![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
elbion AG |
---|---|
Information provided by: | elbion AG |
ClinicalTrials.gov Identifier: | NCT00322803 |
This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.
Condition | Intervention | Phase |
---|---|---|
Panic Disorder |
Drug: ELB139 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment |
Estimated Enrollment: | 24 |
Study Start Date: | May 2006 |
Estimated Study Completion Date: | October 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Charité – University Clinics Berlin | |
Berlin, Germany, 10117 | |
Emovis, The institute of emotional health | |
Berlin, Germany, 10629 | |
Netherlands | |
Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University | |
Maastricht, Netherlands, 6200 MD |
Principal Investigator: | Eric Griez, Prof Dr | Academic Anxiety Center and Department of Psychiatry & Neuropsychology; Maastricht University |
Study ID Numbers: | ELB139202-05, EudraCT Number:2005-005708-17 |
Study First Received: | May 5, 2006 |
Last Updated: | September 27, 2006 |
ClinicalTrials.gov Identifier: | NCT00322803 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
panic disorder proof of concept |
Panic Disorder Anxiety Disorders Mental Disorders |
Pathologic Processes Disease |